AYTU BioPharma
AYTU
64 hedge funds and large institutions have $48.3M invested in AYTU BioPharma in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 5 closing their positions.
440% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 5
283% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 6
142% more call options, than puts
Call options by funds: $368K | Put options by funds: $152K
88% more capital invested
Capital invested by funds: $25.7M → $48.3M (+$22.5M)
52% more funds holding
Funds holding: 42 → 64 (+22)
0.11% more ownership
Funds ownership: 1.25% → 1.36% (+0.11%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.75M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.19M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.05M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$8.22M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$468K |
| 3 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$297K |
| 4 |
Squarepoint
New York
|
-$208K |
| 5 |
Morgan Stanley
New York
|
-$106K |
AYTU Hedge Fund Activity: Q1 2021 in Review
64 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2021, worth a combined $48.3M — up 88% from $25.7M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AYTU positions and 5 closed out — a net gain of 22 holders — while 23 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $10.2M. The largest seller was Stonepine Capital Management, cutting an estimated $8.22M.
- 64 institutional investors held AYTU BioPharma (AYTU) as of Q1 2021, up from 42 in Q4 2020.
- Funds reported $48.3M of AYTU BioPharma stock for Q1 2021, up 88% quarter-over-quarter.
- 27 funds opened new AYTU BioPharma positions in Q1 2021 and 5 closed out, a net change of +22 holders.
- The largest AYTU BioPharma buyer in Q1 2021 was BlackRock, an estimated $10.2M added.
- The largest AYTU BioPharma seller in Q1 2021 was Stonepine Capital Management, an estimated $8.22M sold.
Based on aggregated 13F filings for Q1 2021.